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Abstract Chloroform, a halogenated hydrocarbon, causes
central nervous system depression, cardiac arrhythmias, and
hepatotoxicity. We describe a case of chloroform ingestion
with a confirmatory serum level and resultant hepatotoxicity
successfully treated with intravenously administered N-
acetylcysteine (NAC). A 19-year-old man attempting suicide
ingested approximately 75 mL of chloroform. He was
unresponsive and intubated upon arrival. Intravenously
administered NAC was started after initial stabilization was
complete. His vital signs were normal. Admission laboratory
values revealed normal serum electrolytes, AST, ALT, PT,
BUN, creatinine, and bilirubin. Serum ethanol level was
15 mg/dL, and aspirin and acetaminophen were undetect-
able. The patient was extubated but developed liver function
abnormalities with a peak AST of 224 IU/L, ALT of 583 IU/
L, and bilirubin level reaching 16.3 mg/dL. NAC was
continued through hospital day 6. Serum chloroform level
obtained on admission was 91 μg/mL. The patient was
discharged to psychiatry without known sequelae and normal
liver function tests. The average serum chloroform level in
fatal cases of inhalational chloroform poisoning was 64 μg/
mL, significantly lower than our patient. The toxicity is
believed to be similar in both inhalation and ingestion routes
of exposure, with mortality predominantly resulting from
anoxia secondary to central nervous system depression.
Hepatocellular toxicity is thought to result from free
radical-induced oxidative damage. Previous reports describe
survival after treatment with orally administered NAC, we
report the first use of intravenously administered NAC for
chloroform ingestion. Acute oral ingestion of chloroform is
extremely rare. Our case illustrates that with appropriate
supportive care, patients can recover from chloroform
ingestion, and intravenously administered NAC may be of
benefit in such cases.
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Background
Chloroform, also known as trichloromethane, is one of
many halogenated hydrocarbons. Chloroform was first
discovered in 1831 and was used for general anesthesia
by 1848 [1]. Toxicity from chloroform can include central
nervous system depression, cardiac arrhythmias, hepatic
injury, and hepatic cancer [1]. Most cases of chloroform
toxicity are the result of inhalational exposures, and very
few reports involve oral ingestions. Since this route of
exposure is exceedingly rare, information regarding the
clinical course and management dilemmas of chloroform
ingestions is limited. We describe the successful treatment
of an acute chloroform ingestion with intravenously
administered N-acetylcysteine (NAC) despite having one
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Case Report
A 19-year-old African-American man was found uncon-
scious in his car with a suicide note and a half-empty bottle
of chloroform he had ordered on the internet from overseas
(Fig. 1). He was brought to the emergency department
obtunded and required immediate endotracheal intubation
and mechanical ventilation. It was later determined that he
had drank about 75 mL of the chloroform prior to his being
discovered. His initial vital signs included a heart rate of
75 beats/min and a blood pressure of 113/60 mm Hg; he
was mechanically ventilated at a rate of 16 breaths/min with
an oxygen saturation of 100% on 100% FIO2. His physical
examination was otherwise unremarkable. The patient had
an ECG performed, which did not reveal any signs of
ischemia with a QRS of 86 ms and QT of 408 ms. Cardiac
monitoring did not reveal ectopy. Blood drawn on arrival
revealed a glucose of 135 mg/dL, AST of 18 IU/L, ALT of
10 IU/L, total bilirubin of 1.3 mg/dL, and direct bilirubin of
0.1 mg/dL; PT was 13.6 s (INR 1.16) and had normal
serum electrolytes, BUN, and creatinine. His admission
serum ethanol concentration was 15 mg/dL, and serum
salicylate and acetaminophen concentrations were unde-
tectable. His admission urine drug screen was only positive
for opiates.
The poison center was notified by EMS upon finding the
patient with bottle of chloroform, allowing us to evaluate
the patient at bedside upon arrival in the emergency
department. In light of chloroform’s hepatotoxicity, therapy
with NAC was recommended. The patient was treated with
intravenously administered NAC 150 mg/kg over 1 h,
followed by 50 mg/kg over 4 h, and then was started on an
intravenous drip at a rate of 6.25 mg kg
−1 h
−1.
On the evening of the second hospital day, the patient had
regained consciousness and was successfully extubated. Prior
to extubation, the patient completed 21 h of intravenously
administered NAC finishing the infusion the pharmacy had
prepared.Becausethepatientwasstillintubatedwhenthefirst
infusion of NAC was completed, the decision was made to
continue NAC at 6.25 mg kg
−1 h
−1. We had planned on
stopping the intravenously administered NAC when the
second pre-mixed infusion was finished; however, on
hospital day 3, his total bilirubin began to rise although his
AST and ALT remained normal. Since information on the
Fig. 1 A half-empty bottle of chloroform
Fig. 2 Transaminase trends after ingestion
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144 J. Med. Toxicol. (2010) 6:143–146clinical course of chloroform ingestions is limited, we
continued NAC therapy. On hospital day 4, his serum AST
and ALT began to rise. His total serum bilirubin and PT both
peaked on hospital day 4 at 16.3 mg/dL and 21.3 s (INR
2.25), respectively (Fig. 2). On hospital day 5, his AST and
ALT had peaked at 224 and 583 IU/L, respectively (Fig. 3).
At that time, his total serum bilirubin had fallen to 4.1 mg/
dL, and his PT had declined to 17.7 s (INR 1.87). The
following day, his serum bilirubin, AST, and ALT all began
to decline, and intravenously administered NAC therapy was
stopped. By hospital day 8, the patient’s AST had fallen to
47 IU/L, his ALT had fallen to 231 IU/L, his total serum
bilirubin was 1.1 mg/dL, and his PT had normalized. His
BUN and creatinine remained normal throughout his hospital
course. He was subsequently transferred to an inpatient
psychiatric unit without observed permanent sequelae. His
serum chloroform concentration on admission was later
determined to be 91 μg/mL.
Discussion
Like all halogenated hydrocarbons, chloroform exerts its
anesthetic effects through activation of the GABAA
receptor, causing an influx of chloride ions, hyper-
polarizing the neuron and thereby clinically inducing
sedation [2]. Most fatalities are believed to be the result
of anoxia secondary to deep sedation and impairment of
airway reflexes and respiratory drive [1, 3]. Other observed
effects of these agents can include sensitization of the
myocardium to catecholamines, ventricular arrhythmias,
and delayed hepatotoxicity resulting from free radical
damage to the centrilobular hepatocytes [1, 3]. Besides the
above clinical findings, oral exposure to chloroform can
also cause direct irritation of the oral, esophageal, and
gastro-intestinal mucosa. Associated symptoms include
chest pain, abdominal pain, nausea, and vomiting. If
aspirated, chloroform can also cause symptoms of acute
pneumonitis and acute lung injury [3].
Intravenously administered NAC therapy is commonly
used for intubated patients in our institution. After the
decision to use intravenously administered NAC, we had
limited information on ingestions of chloroform to predict
the duration of hepatotoxicity. Therefore, the NAC
regimen was reassessed daily. His significant elevation
of bilirubin on day 4 was surprising given that fact that his
transaminases had just started to rise. The NAC regimen
used in this case was the identical protocol used in
acetaminophen toxicity. Due to continued abnormalities
with his liver function testing, we continued the regimen
of 6.25 mg kg
−1 h
−1 of intravenously administered NAC
t h e r a p yt h r o u g hh o s p i t a ld a y6u ntil the hepatotoxicity had
clearly improved.
Case reports of oral ingestions of chloroform have been
previously described [1, 3-5]. Other than the direct mucosal
irritant effects described above, oral chloroform toxicity is
believed similar to that of inhaled chloroform [1, 3, 4].
These previous case reports demonstrated average blood
concentrations in fatal chloroform poisonings to have
ranged between 33 and 64 μg/mL. These levels are
significantly lower than that of our patient who went on
to have a complete recovery [1, 6].
The utilization of NAC for chloroform-induced hepato-
toxicity has demonstrated successful outcomes in cases
with mild hepatotoxicity [5, 7]. However, none of these
previous cases utilized the intravenous formulation of
NAC. Because chloroform is believed to cause hepatic
damage by free radical injury and NAC is known to replete
glutathione and scavenge free radicals, it is logical that both
formulations of NAC may decrease hepatic injury second-
ary to chloroform exposure [8, 9].
A recent report describes a case of both chloroform and
dichloromethane ingestion who survived without NAC thera-
py [10]. In this case, chloroform levels were not reported,
but liver function tests peaked with an ASTof 1,617 IU/L
and ALT of 2,677 IU/L on days 4 and 5, respectively.
Additionally, the total bilirubin peaked at 7 mg/dL, and
they report that liver function tests took 4 weeks to return
within normal limits. Without knowing the chloroform
level and further clinical information, it is difficult to
quantify the effects of NAC therapy. However, our patient
presented with a chloroform level well above reports of
previous fatalities, and his AST and ALT peaked at only
224 and 583 IU/L, respectively. Considering that NAC
therapy has such low risk and high theoretical benefit, it
should be considered for use in chloroform and other
halogenated hydrocarbon-induced hepatotoxicity.
In summary, chloroform can cause injury resulting in central
nervous system depression, respiratory depression, direct
mucosalirritation,myocardial sensitization,andhepatotoxicity.
Aggressive treatment with supportive care, with emphasis on
protectingtheairwayandventilation,as well as theuseofNAC
therapy to treat hepatic injury, can result in complete recovery
even with significant elevated chloroform levels.
Open Access This article is distributed under the terms of the
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